Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 11.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more ...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) recently announced the appointment of William T. Andrews, MD, as Chief Medical Officer, a move that coincides with a 13% rise in the company's share price over ...

Below, we take a look at Catalyst Pharmaceutical (CPRX), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the ...

CPRX is a #2 (Buy) on the Zacks Rank, with a VGM Score of A. Additionally, the company could be a top pick for growth investors. CPRX has a Growth Style Score of B, forecasting year-over-year ...

This was the stock's second consecutive day of gains.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more ...

CPRX sits at a Zacks Rank #2 (Buy), holds a Growth Style Score of B, and has a VGM Score of A. Earnings and sales are forecasted to increase 1.8% and 13.9% year-over-year, respectively. Four analysts ...